The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.
Treatment with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance.
Open accessAbstract
Impaired glucose tolerance (IGT) is associated with defects in both insulin secretion and action and carries a high risk for conversion to non-insulin-dependent diabetes mellitus (NIDDM).Troglitazone, an insulin sensitizing agent, reduces glucose concentrations in subjects with NIDDM and IGT but is not known to affect insulin secretion.We sought to determine the role of  cell function in mediating improved glucose tolerance.Obese subjects with IGT received 12 wk of either 400 mg daily of troglitazone ( n ϭ 14) or placebo ( n ϭ 7) in a randomized, double-blind design.Study measures at baseline and after treatment were glucose and insulin responses to a 75-g oral glucose tolerance test, insulin sensitivity index (S I ) assessed by a frequently sampled intravenous glucose tolerance test, insulin secretion rates during a graded glucose infusion, and  cell glucose-sensing ability during an oscillatory glucose infusion.Troglitazone reduced integrated glucose and insulin responses to oral glucose by 10% ( P ϭ 0.03) and 39% ( P ϭ 0.003), respectively.S I increased from 1.3 Ϯ 0.3 to 2.6 Ϯ 0.4 ϫ 10 Ϫ 5 min Ϫ 1 pM Ϫ 1 ( P ϭ 0.005).Average insulin secretion rates adjusted for S I over the glucose interval 5-11 mmol/liter were increased by 52% ( P ϭ 0.02), and the ability of the  cell to entrain to an exogenous oscillatory glucose infusion, as evaluated by analysis of spectral power, was improved by 49% ( P ϭ 0.04).No significant changes in these parameters were demonstrated in the placebo group.In addition to increasing insulin sensitivity, we demonstrate that troglitazone improves the reduced  cell response to glucose characteristic of subjects with IGT.This appears to be an important factor in the observed improvement in glucose tolerance.( J. Clin.Invest.1997.100: 530-537.)Key words: thiazoles • insulin resistance • insulin secretion • non-insulin-dependent diabetes mellitus • glucose intolerance Methods SubjectsThe study design was that of a double blind, placebo-controlled clinical trial in which two subjects were assigned to treatment with troglitazone for every one subject treated with placebo.Randomization was performed by Parke-Davis Pharmaceutical Research Division, Warner Lambert Co. (Ann Arbor, MI), who kindly provided the study medication and placebo.The groups were well matched for age, degree of obesity, and extent of glucose intolerance (for all compari-
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Based on the concept of a feedback loop, it has become evident that subjects who are at high risk of developing Type 2 diabetes have diminished beta-cell function at a time when many of them still have NGT.”
From The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes (2003) · cites this paper as [105]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Spectral Analysis and its Applications.
Freiberger, W. F., Jenkins, G. M., & Watts, D. G. (1969) · Journal of the American Statistical Association · doi:10.2307/2286100 · Cited by 4,990
Lehmann, J. M., Moore, L. B., Smith-Oliver, T. A., Wilkison, W. O., Willson, T. M., & Kliewer, S. A. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.22.12953 · Cited by 3,645
Morgan, C. R., & Lazarow, A. (1963) · Diabetes · doi:10.2337/diab.12.2.115 · Cited by 2,197
Pathogenesis of NIDDM. A balanced overview.
DeFronzo, R. A., Bonadonna, R. C., & Ferrannini, E. (1992) · Diabetes Care · doi:10.2337/diacare.15.3.318 · Cited by 2,085
Kliewer, S. A., Lenhard, J. M., Willson, T. M., Patel, I., Morris, D. C., & Lehmann, J. M. (1995) · Cell · doi:10.1016/0092-8674(95)90194-9 · Cited by 2,028
Bergman, R. N., Phillips, L. S., & Cobelli, C. (1981) · Journal of Clinical Investigation · doi:10.1172/jci110398 · Cited by 1,640
Physical activity and reduced occurrence of non–insulin-dependent diabetes mellitus
Helmrich, S. P., Ragland, D. R., Leung, R. W., & Paffenbarger, R. S. (1991) · New England Journal of Medicine · doi:10.1056/nejm199107183250302 · Cited by 1,634
Kahn, S. E., Prigeon, R. L., McCulloch, D. K., Boyko, E. J., Bergman, R. N., Schwartz, M. W., Neifing, J. L., Ward, W. K., Beard, J. C., & Palmer, J. P. (1993) · Diabetes · doi:10.2337/diab.42.11.1663 · Cited by 1,405
Lipotoxicity in the Pathogenesis of Obesity-Dependent NIDDM: Genetic and Clinical Implications
Unger, R. H. (1995) · Diabetes · doi:10.2337/diab.44.8.863 · Cited by 1,100
Eriksson, K. F., & Lindg�rde, F. (1991) · Diabetologia · doi:10.1007/bf00400196 · Cited by 1,092
Cited by
Sorted by citations
Items 101–200 of 216
Williams, I. M., Otero, Y. F., Bracy, D. P., Wasserman, D. H., Biaggioni, I., & Arnold, A. C. (2016) · Hypertension · doi:10.1161/hypertensionaha.115.06935 · Cited by 42
Polycystic Ovary Syndrome and Hyperandrogenic States
Chang, R. J., & Dumesic, D. A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-47912-7.00021-4 · Cited by 41
Ehrmann, D. A., Breda, E., Cavaghan, M. K., Bajramovic, S., Imperial, J., TOFFOLO, G. M., Cobelli, C., & Polonsky, K. S. (2002) · Diabetologia · doi:10.1007/s00125-002-0776-y · Cited by 41
Self-citationPioglitazone attenuates fatty acid–induced oxidative stress and apoptosis in pancreatic β‐cells
Saitoh, Y., Chun‐ping, C., Noma, K., Ueno, H., Mizuta, M., & Nakazato, M. (2007) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00749.x · Cited by 41
Donnelly, R., & Qu, X. (1998) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.1998.tb02181.x · Cited by 40
Strowig, S. M., & Raskin, P. (2004) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2004.00440.x · Cited by 38
Effect of PPAR-γ Activation and Inhibition on Glucose-Stimulated Insulin Release in INS-1e Cells
Santini, E., Fallahi, P., Ferrari, S. M., Masoni, A., Antonelli, A., & Ferrannini, E. (2004) · Diabetes · doi:10.2337/diabetes.53.suppl_3.s79 · Cited by 39
Long-term glycaemic control with pioglitazone in patients with type 2 diabetes
Campbell, I. W. (2004) · International Journal of Clinical Practice · doi:10.1111/j.1368-5031.2004.0108.x · Cited by 37
Im, S., Kim, J. W., Kim, T. H., Song, X.-L., Kim, S., Kim, H.-I., & Ahn, Y. (2005) · Experimental & Molecular Medicine · doi:10.1038/emm.2005.14 · Cited by 38
Celestina, S. K., Sundaram, K., & Ravi, S. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.103640 · Cited by 37
Toffolo, G., Cefalu, W. T., & Cobelli, C. (1999) · Metabolism · doi:10.1016/s0026-0495(99)90132-4 · Cited by 37
Troglitazone enhances the hepatotoxicity of acetaminophen by inducing CYP3A in rats
Li, J., Kaneko, T., Wang, Y., Qin, L., Wang, P., & Sato, A. (2002) · Toxicology · doi:10.1016/s0300-483x(02)00143-9 · Cited by 36
Frankó, A., Neschen, S., Rozman, J., Rathkolb, B., Aichler, M., Feuchtinger, A., Brachthäuser, L., Neff, F., Kovářová, M., Wolf, E., et al. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2016.12.007 · Cited by 34
The importance of β-cell management in type 2 diabetes
Standl, E. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01360.x · Cited by 34
Parton, L. E., Diraison, F., Neill, S. E., Ghosh, S., Rubino, M. A., Bisi, J., Briscoe, C. P., & Rutter, G. A. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00016.2004 · Cited by 34
Thiazolidinediones in the treatment of Type 2 diabetes
Greenberg, A. S., & Pittas, A. G. (2002) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.3.5.529 · Cited by 34
Gao, Y., She, R., & Sha, W. (2017) · Oncotarget · doi:10.18632/oncotarget.23043 · Cited by 33
Yilmaz, H., Gürsoy, A., Şahi̇n, M., & Demirağ, N. G. (2007) · Acta Diabetologica · doi:10.1007/s00592-007-0004-9 · Cited by 32
Karunakaran, U., Elumalai, S., Moon, J. S., & Won, K. C. (2021) · Redox Biology · doi:10.1016/j.redox.2021.102029 · Cited by 32
Wang, X., Zhou, L., Shao, L., Qian, L., Fu, X., Li, G., Luo, T., Gu, Y., Li, F., Li, J., et al. (2007) · Life Sciences · doi:10.1016/j.lfs.2007.04.034 · Cited by 31
Zangeneh, F., Kudva, Y. C., & Basu, A. (2003) · Mayo Clinic Proceedings · doi:10.4065/78.4.471 · Cited by 31
Redefining the clinical management of type 2 diabetes: matching therapy to pathophysiology
Gerich, J. E. (2002) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.32.s3.6.x · Cited by 31
Expression and functional activity of PPARγ in pancreatic β cells
Welters, H. J., McBain, S. C., Tadayyon, M., Scarpello, J. H. B., Smith, S. A., & Morgan, N. G. (2004) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705844 · Cited by 29
Bloomgarden, Z. T. (2005) · Diabetes Care · doi:10.2337/diacare.28.2.488 · Cited by 29
Buse, J. B., Polonsky, K. S., & Burant, C. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-0324-5.00031-6 · Cited by 28
Self-citationCurrent Views on the Mechanism of Action of Thiazolidinedione Insulin Sensitizers
Goldstein, B. J. (1999) · Diabetes Technology & Therapeutics · doi:10.1089/152091599317189 · Cited by 26
Wagenaar, L. J. (1999) · The Netherlands Journal of Medicine · doi:10.1016/s0300-2977(99)00021-2 · Cited by 25
Troglitazone selectively inhibits glyoxalase I gene expression
Wu, L., Eftekharpour, E., Davies, G. F., Roesler, W. J., & Juurlink, B. H. J. (2001) · Diabetologia · doi:10.1007/s001250100004 · Cited by 24
Rasouli, N., Kern, P. A., Reece, E. A., & Elbein, S. C. (2006) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00221.2006 · Cited by 23
Goldberg, R. B. (1998) · Medical Clinics of North America · doi:10.1016/s0025-7125(05)70025-0 · Cited by 21
Acute exposure of beta-cells to troglitazone decreases insulin hypersecretion via activating AMPK
Deng, R., Nie, A., Jian, F., Liu, Y., Tang, H., Zhang, J., Zhang, Y., Shao, L., Li, F., Zhou, L., et al. (2013) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2013.10.021 · Cited by 20
Risk reduction therapy for syndrome X: Comparison of several treatments
Oron‐Herman, M., Sela, B., & Rosenthal, T. (2005) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2004.10.012 · Cited by 20
Troglitazone ameliorates lipotoxicity in the beta cell line INS-1 expressing PPAR gamma.
Kawai, T., Hirose, H., Seto, Y., Fujita, H., Fujita, H., Ukeda, K., & Saruta, T. (2002) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(01)00367-9 · Cited by 22
A Unifying Organ Model of Pancreatic Insulin Secretion
Gaetano, A. D., Gaz, C., Palumbo, P., & Panunzi, S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0142344 · Cited by 20
Khatami, F., Mohajeri‐Tehrani, M. R., & Tavangar, S. M. (2019) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530319666190228102212 · Cited by 19
Pharmacogenetics of Thiazolidinedione Therapy
Aquilante, C. L. (2007) · Pharmacogenomics · doi:10.2217/14622416.8.8.917 · Cited by 19
Targeting Insulin Resistance and β-Cell Dysfunction: The Role of Thiazolidinediones
Prato, S. D., & Marchetti, P. (2004) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2004.6.719 · Cited by 19
Thiazolidinediones and Insulin
Huang, A., & Raskin, P. (2005) · Treatments in Endocrinology · doi:10.2165/00024677-200504040-00002 · Cited by 19
Effects of Troglitazone in Young First-Degree Relatives of Patients With Type 2 Diabetes
Levin, K., Nielsen, O. H., Henriksen, J. E., & Beck‐Nielsen, H. (2004) · Diabetes Care · doi:10.2337/diacare.27.1.148 · Cited by 18
Garg, R., Gopal, J., & Jones, G. R. (2006) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2005.10.004 · Cited by 17
Fiévet, C., & Staels, B. (2009) · Current Atherosclerosis Reports · doi:10.1007/s11883-009-0043-5 · Cited by 16
Comaschi, M., Demicheli, A., Pietro, C. D., Bellatreccia, A., Mariz, S., & the COM06 Study Investigators (2007) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2006.0023 · Cited by 16
Kim, D., Ahn, B., Kim, Y. S., Hur, D. Y., Yang, J. W., Park, G. B., Jang, J. E., Lee, E. J., Kwon, M. J., Kim, T. N., et al. (2019) · Journal of Diabetes Research · doi:10.1155/2019/2376512 · Cited by 15
Chronic Pancreatitis and Diabetes Mellitus
Lin, Y. K., Johnston, P. C., Arce, K. M., & Hatipoğlu, B. (2015) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-015-0055-x · Cited by 17
Evaluation of β‐cell mass and function in the Göttingen minipig
Larsen, M. O., Rolin, B., Raun, K., Knudsen, L., Gotfredsen, C., & Bock, T. (2007) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00785.x · Cited by 13
Bayesian Identification of a Population Compartmental Model of C-Peptide Kinetics
Magni, P., Bellazzi, R., Sparacino, G., & Cobelli, C. (2000) · Annals of Biomedical Engineering · doi:10.1114/1.1289459 · Cited by 15
The possible role of leucine in modulating glucose homeostasis under distinct catabolic conditions
Zanchi, N. E., Guimarães‐Ferreira, L., de Siqueira-Filho, M. A., Camporez, J. P., Nicastro, H., Chaves, D. F. S., de Campos‐Ferraz, P. L., Lancha, A. H., & Carvalho, C. R. D. O. (2012) · Medical Hypotheses · doi:10.1016/j.mehy.2012.09.018 · Cited by 14
Giuseppe, G. D., Ciccarelli, G., CEFALO, C. M. A., Cinti, F., Moffa, S., Impronta, F., Capece, U., Pontecorvi, A., Giaccari, A., & Mezza, T. (2021) · Minerva Endocrinology · doi:10.23736/s2724-6507.21.03405-9 · Cited by 17
Hirsch, D., Odorico, J. S., Danobeitia, J. S., Alejandro, R., Rickels, M. R., Hanson, M. S., Radke, N. A., Baidal, D. A., Hullett, D. A., Naji, A., et al. (2012) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2011.03947.x · Cited by 14
Comparison of metformin and thiazolidinediones in the management of polycystic ovary syndrome
Baillargeon, J., Iuorno, M. J., & Nestler, J. E. (2002) · Current Opinion in Endocrinology & Diabetes · doi:10.1097/00060793-200208000-00003 · Cited by 14
Li, Y., An, H.-X., Deng, X., Chen, L., & Li, Z. (2003) · PubMed · Cited by 14
Galatsis, P. (1998) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(08)61097-0 · Cited by 14
Goacutemez-Peacuterez, F. J., Aguilar-Salinas, C. A., V[aacute]zquez-Ch[aacute]vez, C., nel-Salmoacuten, G. F., Gallegos-Mart[iacute]nez, J., Goacutemez-Diaz, R. A., Orozco, S. S., Chavira-Loacutepez, I. J., Saacutenchez-Reyes, L., Torres-Acosta, E. M., et al. (2002) · Metabolism · doi:10.1053/meta.2002.29024 · Cited by 13
Yandrapalli, S., Jolly, G. P., Horblitt, A. M., Pemmasani, G., Sanaani, A., Aronow, W. S., & Frishman, W. H. (2020) · Cardiology in Review · doi:10.1097/crd.0000000000000308 · Cited by 12
Can thiazolidinediones delay disease progression in type 2 diabetes?
Leiter, L. A. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x112507 · Cited by 12
Clinical Outcomes in Metabolic Syndrome
Bhatheja, R., & Bhatt, D. L. (2006) · The Journal of Cardiovascular Nursing · doi:10.1097/00005082-200607000-00011 · Cited by 12
Addressing the insulin secretion defect: A logical first-line approach
Gerich, J. E. (2000) · Metabolism · doi:10.1053/meta.2000.17824 · Cited by 12
Beta‐cell function in type 2 diabetes ( T2DM ): Can it be preserved or enhanced?
Kassem, L. S., Rajpal, A., Barreiro, M. V. E., & Ismail‐Beigi, F. (2023) · Journal of Diabetes · doi:10.1111/1753-0407.13446 · Cited by 14
Effect of Weight Loss on the Pulsatile Insulin Secretion
Zˇarković, M., Ćirić, J., Penezić, Z., Trbojević, B., & Drezgić, M. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.10.6919 · Cited by 11
Combination Therapy in Type 2 Diabetes
Bajaj, M., & DeFronzo, R. A. (2004) · Wiley eBooks · doi:10.1002/0470862092.d0613 · Cited by 11
Investigational agents that protect pancreatic islet β-cells from failure
Aston‐Mourney, K., Proietto, J., & Andrikopoulos, S. (2005) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.14.10.1241 · Cited by 10
Role of PPARG (Pro12Ala) in Malaysian type 2 diabetes mellitus patients
Paramasivam, D., Safi, S. Z., Qvist, R., Abidin, I. B. Z., Hairi, N. N., & Chinna, K. (2016) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-015-0462-5 · Cited by 9
Preserving insulin secretion in Type 2 diabetes mellitus
Tibaldi, J. M. (2008) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.3.2.147 · Cited by 8
Prasad, P. S., Imam, S. S., Aqil, M., Rizwan, M., Sultana, Y., & Ali, A. (2015) · Journal of Analytical Chemistry · doi:10.1134/s106193481506012x · Cited by 8
β‐Cell Dysfunction in Type 2 Diabetes
Utzschneider, K. M., & Kahn, S. E. (2003) · Wiley eBooks · doi:10.1002/0470862092.d0403 · Cited by 8
Prevention of Type 2 Diabetes Insulin Resistance and -Cell Function
Chiasson, J. L., & RABASA-LHORET, R. P. R. (2004) · Cited by 7
Copperman, A. B., Mukherjee, T., & KASE, N. G. (2003) · Elsevier eBooks · doi:10.1016/b978-012053642-9/50029-6 · Cited by 7
Zawalich, W. S., Tesz, G. J., & Zawalich, K. C. (2003) · Metabolism · doi:10.1016/s0026-0495(03)00317-2 · Cited by 7
Regulation of Insulin Secretion in Vivo
Vidal, J., & Kahn, S. E. (2001) · Endocrine updates · doi:10.1007/978-1-4615-1597-5_7 · Cited by 7
Genetic contributions to glucose intolerance in polycystic ovary syndrome
Ehrmann, D. A. (2004) · Reproductive BioMedicine Online · doi:10.1016/s1472-6483(10)62106-2 · Cited by 7
Self-citationPrevention of Type 2 Diabetes Mellitus
Simpson, R. W., Tuomilehto, J. O., Lindström, J., Shaw, J. E., & Zimmet, P. (2003) · Wiley eBooks · doi:10.1002/0470862092.d1118 · Cited by 7
The clinical effectiveness and cost effectiveness of rosiglitazone for type 2 diabetes mellitus
Lord, J. L., Paisley, S., & Taylor, R. (2000) · Brunel University Research Archive (BURA) (Brunel University London) · Cited by 7
Prediabetes in sub-saharan Africa: Pathophysiology, predictors, and prevalence
Young, E., & Nwatu, C. (2020) · Nigerian Journal of Medicine · doi:10.4103/njm.njm_30_20 · Cited by 7
Insulin signalling through ultradian oscillations
Lévy, J. (2001) · Growth Hormone & IGF Research · doi:10.1016/s1096-6374(01)80004-6 · Cited by 6
Suárez, R. M. G., Amador, P., & Calzado, C. M. A. (2010) · Revista cubana de endocrinología · Cited by 5
Die Insulinresistenz beim polyzystischen Ovar-Syndrom
Schröder, A. K., Tauchert, S., Ortmann, O., Diedrich, K., & Weiss, J. M. (2003) · Wiener klinische Wochenschrift · doi:10.1007/bf03041041 · Cited by 6
Treating diabetes using oral agents
Malik, T., & Trence, D. (2003) · Primary Care Clinics in Office Practice · doi:10.1016/s0095-4543(03)00039-3 · Cited by 6
Tobin, B. W., & Miller, G. D. (2001) · Journal of Nutrition · doi:10.1093/jn/131.2.333s · Cited by 6
DeFronzo, R. A. (2003) · The British Journal of Diabetes · doi:10.1177/1474651403003001s0601 · Cited by 5
Hupfeld, C. J., & Olefsky, J. M. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-18907-1.00040-8 · Cited by 7
Tiazolidinedionas. Beneficios y riesgos reales
Hernández-Jiménez, S. C., Aguilar-Salinas, C. A., & Gomez-Perez, F. J. (2002) · Revista de Endocrinología y Nutrición · Cited by 4
Hupfeld, C. J., Courtney, C. H., & Olefsky, J. M. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-5583-9.00041-1 · Cited by 5
STOLAR, M. W. (2009) · Clinical Medicine Therapeutics · doi:10.4137/cmt.s2370 · Cited by 3
Approaches to preventing mealtime hyperglycaemic excursions
Kelley, D. E. (2002) · Diabetes Obesity and Metabolism · doi:10.1046/j.1463-1326.2002.00172.x · Cited by 3
Bays, H. E., Mandarino, L. J., & DeFronzo, R. A. (2004) · Cited by 3
Variability in Estimated Modelled Insulin Secretion
Ormsbee, J. J., Burden, H. J., Knopp, J. L., Chase, J. G., Murphy, R., Shepherd, P. R., & Merry, T. L. (2021) · Journal of Diabetes Science and Technology · doi:10.1177/1932296821991120 · Cited by 3
Davidson, M. B. (2005) · New England Journal of Medicine · doi:10.1056/nejm200501133520222 · Cited by 3
Xiang, Q., Guo, P., Tian, Q., Liang, Y., Zhang, F., Zhuo, L., Yang, Y., Zhao, C., Zhang, Y., & Lei, L. (2026) · Scientific Reports · doi:10.1038/s41598-026-36679-9 · Cited by 2
An aerosolized dual-action autotaxin inhibitor-PPARγ agonist for the treatment of pulmonary fibrosis
Matralis, A. N., Stylianaki, E.-A., Ladopoulou, E. M., Kanellopoulou, P., Smyrniotis, S., Magkrioti, C., Papavasileiou, K. D., Willems, S., Pabon, J. P. R., Nastos, D., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102778 · Cited by 2
American Association of Clinical Endocrinologists Meeting, May 2002
Bloomgarden, Z. T. (2002) · Diabetes Care · doi:10.2337/diacare.25.8.1464 · Cited by 2
A modelling approach to hepatic glucose production estimation
Panunzi, S., & Gaetano, A. D. (2022) · PLoS ONE · doi:10.1371/journal.pone.0278837 · Cited by 2
Lipids and Glucose in Type 2 Diabetes: What About the β-Cell and the Mitochondria?
Eldor, R., & Raz, I. (2005) · Diabetes Care · doi:10.2337/diacare.28.4.985 · Cited by 2
Pørksen, N. K., Hollingdal, M., Juhl, C. B., Butler, P. C., Veldhuis, J. D., & Schmitz, O. (2002) · Cited by 1
Differentially Expressed Proteins in the Pancreas of Diabetic Mice
Qiu, L. (2005) · OhioLink ETD Center (Ohio Library and Information Network) · Cited by 1
Insulin-Sensitizing and Insulin-Sparing Drugs: Thiazolidinediones and Metformin
Jabbour, S. A. (2006) · Elsevier eBooks · doi:10.1016/b978-1-4160-0273-4.50029-1 · Cited by 1
New therapeutic approaches to revering insuiln resistance
Sonnenberg, G. E., & Kotchen, T. A. (1998) · Current Opinion in Nephrology & Hypertension · doi:10.1097/00041552-199809000-00011 · Cited by 1
Irum, R., Qureshi, G., Dilawar, A., Khurshid, R., & Khawar, S. (2016) · Annals of King Edward Medical University · doi:10.21649/akemu.v22i3.1402 · Cited by 1
Enhancing insulin action: From chemical elements to thiazolidinediones
Perfetti, R., & Chamie, K. (2001) · Journal of Endocrinological Investigation · doi:10.1007/bf03343858 · Cited by 1
C-Peptide Profiling and Type 2 Diabetes Treatment Decisions
Braithwaite, S. S. (1999) · Endocrine Practice · doi:10.4158/ep.5.6.371 · Cited by 1
Sankaran, K. R., Oruganti, L., Ganjayi, M. S., Chintha, V., Muppuru, M. K., Chippada, A. R., Badri, K. R., & Meriga, B. (2021) · Research Square · doi:10.21203/rs.3.rs-302339/v1 · Cited by 1
Metadata
- Authors
- Cavaghan, M. K., Ehrmann, D. A., Byrne, M. M., & Polonsky, K. S.
- Affiliations
- University of Chicago (US)
- ORCID
- Byrne, M M
- Venue
- Journal of Clinical Investigation
- Published
- 1997-08-01
- Volume
- 100
- Issue
- 3
- Pages
- 530-537
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC508219
- OpenAlex
- W2085390992
- Cited by
- 216
- References
- 63
- Citations by year
- 2026: 4 · 2023: 1 · 2022: 1 · 2021: 4 · 2020: 4 · 2019: 3 · 2017: 4 · 2016: 5 · 2015: 6 · 2014: 3 · 2013: 2 · 2012: 5
- FWCI
- 10.73
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5k08dk002315-02)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK-31842, DK 20595, DK-02315)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- troglitazone, impaired glucose tolerance, beta-cell function, insulin secretion, insulin sensitivity, insulin resistance, type 2 diabetes, glucose tolerance, thiazolidinediones, oral glucose tolerance test, insulin sensitivity index, insulin secretion rate, type 2 diabetes prevention, insulin sensitizers
- MeSH terms
- Troglitazone, Administration, Oral, Adult, Animals, Chromans, Double-Blind Method, Female, Glucose, Glucose Tolerance Test, Guinea Pigs, Humans, Hypoglycemic Agents, Islets of Langerhans, Male, Middle Aged, Thiazoles, Treatment Outcome, Glucose Intolerance, Thiazolidinediones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
